LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a ...
Go-forward strategy will emphasize topline revenue growth and future profitability. Company to reduce total operating costs by an estimated 15% in fiscal year 2025. The restructuring will allow ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results